Why Biogen Stock Got Mashed on Monday
Healthcare company (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in its first quarter, which will directly affect its bottom line. By the end of the day, Biogen's stock had lost nearly 3% of its value.
Before market open, Biogen divulged in a regulatory filing that it expects to record $34 million in pre-tax expenses in its first quarter of this year. These consist of in-process research and development costs, as well as upfront and milestone payments.
Image source: Getty Images.
Source Fool.com
Biogen Inc. Aktie
152,80 €
-0,91 %
Die Community liebt Biogen Inc.: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Für Biogen Inc. ergibt sich ein leicht positives Potenzial, angesichts eines Kursziels von 181 € im Vergleich zu 152.8 €.
